Polyrizon Completes Participant Enrollment In Its Trial Of NASARIX To Treat Airborne Allergens
Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a clinical-stage biotechnology company specializing in the development of innovative intranasal hydrogels, today announced the successful
Polyrizon finished signing up all the patients for its allergy medicine test. When a company completes a big study step, it shows progress toward proving if the medicine works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.